Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers

Sven Asmussen, Michael Salter, Donald Prough, George Kramer, Christer Svensen, Melinda Sheffield-Moore, Michael Kinsky

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The primary goal of fluid therapy is to maintain fluid homeostasis. Commonly used isotonic crystalloids are only marginally effective and contribute to fluid excess syndrome. In patients with decreased cardiovascular reserve, fluid therapy alone is not sufficient to maintain end-organ perfusion. Therefore, inotropes or vasoactive drugs are used to supplement fluid infusion. Recent animal data suggest that coinfusion of adrenergic agents modulate the distribution of fluid between the vascular and extravascular/interstitial compartments after a fluid bolus. We sought to determine if this effect would translate in humans by coadministering a β-adrenergic agonist with fluid. Methods: Nine healthy volunteers (aged 21-50 years) were randomly paired and received either a continuous isoproterenol infusion (ISO: 0.05 μg/kg per minute) or 0.9% saline (control [CON]) 30min prior to a 25 mL/kg 0.9% NaCl fluid bolus. Hemodynamics, ventricular volume and function, and microcirculatory determinants (capillary filtration coefficient and oncotic pressure) were measured. Vascular and extravascular volume and fluid balance were determined. Results: Compared with CON, ISO significantly increased heart rate (CON: 64.2 ± 4.1 beats/min vs. ISO: 97.4 ± 5.7 beats/min) and cardiac output (CON: 4.4 ± 0.7 L/min vs. ISO: 10.2 ± 0.9) before fluid bolus. Isoproterenol significantly increased urinary output (ISO: 10.86 ± 1.95 vs. control: 6.53 ± 1.45 mL/kg) and reduced extravascular volume (7.98 ± 2.0 vs. 14.15 ± 1.1mL/kg). Isoproterenol prevented an increase in capillary filtration coefficient (1.74 ± 0.4 vs. 3.21 ± 0.4 mL/min per mmHg · 10). Conclusions: Isoproterenol, a nonselective β-adrenergic agonist, augments vascular volume expansion and eliminates extravascular volume via enhanced diuresis, which may in part be due to enhanced endothelial barrier function.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalShock
Volume42
Issue number5
DOIs
StatePublished - Nov 12 2014

Fingerprint

Isoproterenol
Blood Vessels
Healthy Volunteers
Adrenergic Agonists
Fluid Therapy
Water-Electrolyte Balance
Ventricular Function
Diuresis
Cardiac Output
Adrenergic Agents
Homeostasis
Perfusion
Heart Rate
Hemodynamics
Pressure
crystalloid solutions
Pharmaceutical Preparations

Keywords

  • fluid therapy
  • healthy volunteers
  • isoproterenol
  • Resuscitation
  • βadrenergic agonist

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers. / Asmussen, Sven; Salter, Michael; Prough, Donald; Kramer, George; Svensen, Christer; Sheffield-Moore, Melinda; Kinsky, Michael.

In: Shock, Vol. 42, No. 5, 12.11.2014, p. 407-414.

Research output: Contribution to journalArticle

Asmussen, Sven ; Salter, Michael ; Prough, Donald ; Kramer, George ; Svensen, Christer ; Sheffield-Moore, Melinda ; Kinsky, Michael. / Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers. In: Shock. 2014 ; Vol. 42, No. 5. pp. 407-414.
@article{18c842e9ede04350a1c3095ad5fb3c46,
title = "Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers",
abstract = "Background: The primary goal of fluid therapy is to maintain fluid homeostasis. Commonly used isotonic crystalloids are only marginally effective and contribute to fluid excess syndrome. In patients with decreased cardiovascular reserve, fluid therapy alone is not sufficient to maintain end-organ perfusion. Therefore, inotropes or vasoactive drugs are used to supplement fluid infusion. Recent animal data suggest that coinfusion of adrenergic agents modulate the distribution of fluid between the vascular and extravascular/interstitial compartments after a fluid bolus. We sought to determine if this effect would translate in humans by coadministering a β-adrenergic agonist with fluid. Methods: Nine healthy volunteers (aged 21-50 years) were randomly paired and received either a continuous isoproterenol infusion (ISO: 0.05 μg/kg per minute) or 0.9{\%} saline (control [CON]) 30min prior to a 25 mL/kg 0.9{\%} NaCl fluid bolus. Hemodynamics, ventricular volume and function, and microcirculatory determinants (capillary filtration coefficient and oncotic pressure) were measured. Vascular and extravascular volume and fluid balance were determined. Results: Compared with CON, ISO significantly increased heart rate (CON: 64.2 ± 4.1 beats/min vs. ISO: 97.4 ± 5.7 beats/min) and cardiac output (CON: 4.4 ± 0.7 L/min vs. ISO: 10.2 ± 0.9) before fluid bolus. Isoproterenol significantly increased urinary output (ISO: 10.86 ± 1.95 vs. control: 6.53 ± 1.45 mL/kg) and reduced extravascular volume (7.98 ± 2.0 vs. 14.15 ± 1.1mL/kg). Isoproterenol prevented an increase in capillary filtration coefficient (1.74 ± 0.4 vs. 3.21 ± 0.4 mL/min per mmHg · 10). Conclusions: Isoproterenol, a nonselective β-adrenergic agonist, augments vascular volume expansion and eliminates extravascular volume via enhanced diuresis, which may in part be due to enhanced endothelial barrier function.",
keywords = "fluid therapy, healthy volunteers, isoproterenol, Resuscitation, βadrenergic agonist",
author = "Sven Asmussen and Michael Salter and Donald Prough and George Kramer and Christer Svensen and Melinda Sheffield-Moore and Michael Kinsky",
year = "2014",
month = "11",
day = "12",
doi = "10.1097/SHK.0000000000000233",
language = "English (US)",
volume = "42",
pages = "407--414",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers

AU - Asmussen, Sven

AU - Salter, Michael

AU - Prough, Donald

AU - Kramer, George

AU - Svensen, Christer

AU - Sheffield-Moore, Melinda

AU - Kinsky, Michael

PY - 2014/11/12

Y1 - 2014/11/12

N2 - Background: The primary goal of fluid therapy is to maintain fluid homeostasis. Commonly used isotonic crystalloids are only marginally effective and contribute to fluid excess syndrome. In patients with decreased cardiovascular reserve, fluid therapy alone is not sufficient to maintain end-organ perfusion. Therefore, inotropes or vasoactive drugs are used to supplement fluid infusion. Recent animal data suggest that coinfusion of adrenergic agents modulate the distribution of fluid between the vascular and extravascular/interstitial compartments after a fluid bolus. We sought to determine if this effect would translate in humans by coadministering a β-adrenergic agonist with fluid. Methods: Nine healthy volunteers (aged 21-50 years) were randomly paired and received either a continuous isoproterenol infusion (ISO: 0.05 μg/kg per minute) or 0.9% saline (control [CON]) 30min prior to a 25 mL/kg 0.9% NaCl fluid bolus. Hemodynamics, ventricular volume and function, and microcirculatory determinants (capillary filtration coefficient and oncotic pressure) were measured. Vascular and extravascular volume and fluid balance were determined. Results: Compared with CON, ISO significantly increased heart rate (CON: 64.2 ± 4.1 beats/min vs. ISO: 97.4 ± 5.7 beats/min) and cardiac output (CON: 4.4 ± 0.7 L/min vs. ISO: 10.2 ± 0.9) before fluid bolus. Isoproterenol significantly increased urinary output (ISO: 10.86 ± 1.95 vs. control: 6.53 ± 1.45 mL/kg) and reduced extravascular volume (7.98 ± 2.0 vs. 14.15 ± 1.1mL/kg). Isoproterenol prevented an increase in capillary filtration coefficient (1.74 ± 0.4 vs. 3.21 ± 0.4 mL/min per mmHg · 10). Conclusions: Isoproterenol, a nonselective β-adrenergic agonist, augments vascular volume expansion and eliminates extravascular volume via enhanced diuresis, which may in part be due to enhanced endothelial barrier function.

AB - Background: The primary goal of fluid therapy is to maintain fluid homeostasis. Commonly used isotonic crystalloids are only marginally effective and contribute to fluid excess syndrome. In patients with decreased cardiovascular reserve, fluid therapy alone is not sufficient to maintain end-organ perfusion. Therefore, inotropes or vasoactive drugs are used to supplement fluid infusion. Recent animal data suggest that coinfusion of adrenergic agents modulate the distribution of fluid between the vascular and extravascular/interstitial compartments after a fluid bolus. We sought to determine if this effect would translate in humans by coadministering a β-adrenergic agonist with fluid. Methods: Nine healthy volunteers (aged 21-50 years) were randomly paired and received either a continuous isoproterenol infusion (ISO: 0.05 μg/kg per minute) or 0.9% saline (control [CON]) 30min prior to a 25 mL/kg 0.9% NaCl fluid bolus. Hemodynamics, ventricular volume and function, and microcirculatory determinants (capillary filtration coefficient and oncotic pressure) were measured. Vascular and extravascular volume and fluid balance were determined. Results: Compared with CON, ISO significantly increased heart rate (CON: 64.2 ± 4.1 beats/min vs. ISO: 97.4 ± 5.7 beats/min) and cardiac output (CON: 4.4 ± 0.7 L/min vs. ISO: 10.2 ± 0.9) before fluid bolus. Isoproterenol significantly increased urinary output (ISO: 10.86 ± 1.95 vs. control: 6.53 ± 1.45 mL/kg) and reduced extravascular volume (7.98 ± 2.0 vs. 14.15 ± 1.1mL/kg). Isoproterenol prevented an increase in capillary filtration coefficient (1.74 ± 0.4 vs. 3.21 ± 0.4 mL/min per mmHg · 10). Conclusions: Isoproterenol, a nonselective β-adrenergic agonist, augments vascular volume expansion and eliminates extravascular volume via enhanced diuresis, which may in part be due to enhanced endothelial barrier function.

KW - fluid therapy

KW - healthy volunteers

KW - isoproterenol

KW - Resuscitation

KW - βadrenergic agonist

UR - http://www.scopus.com/inward/record.url?scp=84930060580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930060580&partnerID=8YFLogxK

U2 - 10.1097/SHK.0000000000000233

DO - 10.1097/SHK.0000000000000233

M3 - Article

VL - 42

SP - 407

EP - 414

JO - Shock

JF - Shock

SN - 1073-2322

IS - 5

ER -